Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia
Authors:
- Christie BallantyneCBChristie Ballantyne
- Gilbert GleimGGGilbert Gleim
- Nancy LiuNLNancy Liu
- Christine McCrary SiskCSChristine McCrary Sisk
- Amy O. Johnson-LevonasAJAmy O. Johnson-Levonas
- Yale MitchelYMYale Mitchel
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 6 (3) , 235-243
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final ReportCirculation, 2002
- High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery diseaseAmerican Heart Journal, 2002
- Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary DiseaseNew England Journal of Medicine, 2001
- Relationship of Baseline Serum Cholesterol Levels in 3 Large Cohorts of Younger Men to Long-term Coronary, Cardiovascular, and All-Cause Mortality and to LongevityJAMA, 2000
- Triglycerides are more important in atherosclerosis than epidemiology has suggestedAtherosclerosis, 1998
- Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia∗∗See Appendix for list of principal investigators, study sites, and laboratory sites.The American Journal of Cardiology, 1998
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998
- Triglyceride Concentration and Ischemic Heart DiseaseCirculation, 1998
- Hypertriglyceridemia as a Cardiovascular Risk FactorThe American Journal of Cardiology, 1998
- Clofibrate and Niacin in Coronary Heart DiseaseJAMA, 1975